Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients

Megna, Matteo; Camela, Elisa; Battista, Teresa; Genco, Lucia; Martora, Fabrizio; Noto, Matteo; Picone, Vincenzo; Ruggiero, Angelo; Monfrecola, Giuseppe; Fabbrocini, Gabriella; Potestio, Luca

doi:10.1080/14740338.2023.2173170

Cited by 42 publications

(40 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psoriasis management may be challenging, particularly for moderate-to-severe forms of the disease. 32 , 33 Despite the use of biological drugs and OSM revolutionized the treatment options showing promising results in terms of effectiveness and safety, 34–36 also during the COVID-19 pandemic period which brought further challenges to the daily clinical practice, 37–41 there is still a need for new therapies that are always welcome in order to tailor the treatment to the patient and to have a higher level of performance, especially in order to maintain long-term effectiveness. Indeed, conventional systemic treatments are often avoided for contraindications or the risk of AEs, 8 , 9 phototherapy is often limited by logistic concerns.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature

Potestio¹,

Ruggiero²,

Fabbrocini³

et al. 2023

PTT

Self Cite

View full text Add to dashboard Cite

Psoriasis management may be challenging, particularly for moderate-to-severe forms of the disease. Indeed, conventional systemic treatments are often avoided for contraindications or the risk of adverse events as well as phototherapy is often limited by logistic concerns. Despite the development of biological drugs and small molecules revolutionized the treatment options showing promising results in terms of safety and effectiveness, some limitations remain. Thus, there is still a need for new therapies that are always welcome in order to tailor the treatment to the patient and to have a higher level of performance, especially in order to maintain long-term effectiveness. In this scenario, deucravacitinib, an oral small molecule which selectively inhibits Tyrosine Kinase 2, may represent a promising weapon in psoriasis management. The aim of our manuscript is to review the current knowledge on the efficacy and safety of deucravacitinib for the management of psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature

Potestio¹,

Ruggiero²,

Fabbrocini³

et al. 2023

PTT

Self Cite

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7] On consequence, early diagnosis and appropriate treatment play a key role. 8,9 Even if mild forms of disease are usually treated with topicals, systemic treatments are often required for moderate-to -severe forms of the disease. 10,11 However, conventional systemic drugs (acitretin, cyclosporine, methotrexate, dimethyl fumarate) are often contraindicated or linked to adverse events.…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

Potestio¹,

Fabbrocini²,

Battista³

et al. 2023

PTT

Self Cite

View full text Add to dashboard Cite

The introduction of biologic drugs revolutionized the treatment of psoriasis, shifting treatment goals to higher treatment outcomes and less frequent safety issues. The outbreak of Coronavirus disease 2019 (COVID-19) represented a worldwide challenge, strongly affecting lifestyle, global economy, and overall health. Among the strategies adopted to contain the spreading of the infection, vaccination is the main one. In this context, the introduction of COVID-19 vaccines raised several doubts about their effectiveness and safety in patients undergoing therapy with biological for psoriasis. Even if molecular and cellular mechanisms by which COVID-19 vaccines lead to psoriasis development have not yet been fully elucidated, vaccination itself can trigger the release of interleukin (IL)-6, interferon (IFN) and tumor necrosis factor (TNF) α by T-helper (Th)1/Th17 cells. All these cytokines are involved in psoriasis pathogenesis. Thus, the aim of this manuscript is to review current literature on the safety and effectiveness of COVID-19 vaccination in psoriasis patients undergoing treatment with biologics, in order to clarify any concerns.

show abstract

“…ACH is also resistant to many conventional topical and systemic anti-psoriatic therapies, such as calcineurin inhibitors, phototherapy and methotrexate. 1 , 2 However, the introduction of biological agents has revolutionized the treatment of psoriasis, even in children and elderly patients, in whom they have demonstrated excellent efficacy and safety, 3 , 4 thus making them viable for the therapy of ACH.…”

Section: Introductionmentioning

confidence: 99%

Acrodermatitis Continua of Hallopeau Successfully Treated with Ustekinumab: A Case Report and Literature Review

Shi¹,

Zeng²,

Huang³

et al. 2023

CCID

View full text Add to dashboard Cite

Acrodermatitis continua of Hallopeau (ACH) is a rare variant of pustular psoriasis that presents as a sterile pustular eruption of the periungual and subungual regions. It affects the skin and nail bed and can lead to distal phalangeal destruction as the disease progresses. ACH is an incurable disease that requires long-term maintenance therapy to prevent any complications. Because ACH is a variant of pustular psoriasis, it is commonly treated with anti-psoriatic therapies. Unfortunately, it is resistant to many available anti-psoriatic therapies, and there are no clinical guidelines for it; the treatment is therefore highly challenging. Current treatment strategies are mostly based on a few case reports and case series. In this study, we present a case of ACH in a 24-year-old man with a long history of severe skin lesions and overt onychodystrophy, successfully treated with Ustekinumab. In this patient, we observed rapid improvement in skin lesions and symptoms. Ustekinumab can considerably improve other symptoms besides plaque psoriasis. The treatment and excellent outcomes of Ustekinumab may provide clinical benefits to more patients and serve as a reference for other dermatologists.

show abstract

Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients

Cited by 42 publications

References 76 publications

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

Acrodermatitis Continua of Hallopeau Successfully Treated with Ustekinumab: A Case Report and Literature Review

Contact Info

Product

Resources

About